Droplet IV Information

Droplet IV is a need-driven MedTech start-up founded by doctors and engineers. Droplet started in the BioMedical Design Novo Nordisk Foundation Fellowship Programme and is currently in the Venture House incubator program at BioInnovation Institute. Problem: ≈20% of intravenous (IV) medicine is trapped as residual medicine in IV lines and never reaches the patient leading to significant underdosing. To mitigate this patient risk, nurses must spend an avg. of 2-3 minutes to flush each IV line manually. This is unrealistic and not scalable with the growing global nurse shortage. Solution: Droplet ensures that patients receive the full prescribed dose of medicine every time by automatically flushing IV lines. Market: There are globally more than 6B IV infusions annually and no true automatic flushing products are on the market today. Value propositions of automatic IV line flushing by Droplet: 💧No dangerous underdosing by guaranteeing infusion of the full prescribed dose 💧Decreases the number of nurse tasks and reduces multitasking which saves 3 min. per infusion 💧Ensure golden standard IV treatment for all patients 💧Removes the cost of wasted medicine 💧Fights antibiotic resistance by removing antibiotics ending up in nature as waste and eliminating underdosing. Factors that drive antibiotic resistance As a company, we focus on creating a strong holistic company culture. Personal and professional learning is a priority in Droplet. As we normally say here in Droplet: Medicine belongs in patients - not in the trash! Please don't hesitate to get in touch should you have any questions. On behalf of everybody here at team Droplet 💧 Tore & Marcus Tore@dropletiv.com Marcus@dropletiv.com